The psychologist and researcher José A. Muñoz-Moreno has attended the 7th International Symposium on Neuropsychiatry and HIV held on June 13 and 14 in Barcelona. He performed three presentations on the detection of HIV-associated cognitive impairment.
He presented a paper entitled "Accuracy of NEU Screen to detect cognitive impairment in patients with HIV who are in virologic suppression," which had already produced a poster for the last CROI (Conference on Retroviruses and Opportunistic Infections). In this symposium, the poster has been extended in an oral communication.
In addition, Muñoz-Moreno conducted a plenary session on screening instruments for cognitive impairment associated with HIV and participated at the national meeting of the Working Group on HIV and Central Nervous System (he is one of its coordinators).
With the development of antiretroviral therapy and increased life expectancy of people with HIV, there have been important advances in the understanding of the effects that the virus itself and medication can have on the central nervous system (CNS) . From the first weeks of infection, HIV can cause alterations in a motor and cognitive level, with a large negative impact on quality of life and daily functioning of those who suffer them.
One of the major challenges for physicians and psychologists who work with these patients is to diagnose these deficits as soon as possible. To do this, various clinical factors might be considered, mainly the number of CD4 cells in the blood or the time lived with HIV. However, the evaluation through properly validated neuropsychological testing are the most recommended clinical method for diagnosing such problems.
In this context, researchers from the Fight AIDS Foundation led by psychologist José A. Muñoz-Moreno, submitted in August 2013 a new clinical method for early detection of abnormalities that HIV can cause in the central nervous system; the NEU Screen. Its usefulness has been recognized internationally.